Lampropoulos Fred P.

SEC source: 0000901534-25-000011 · form4-11262025_081100.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,019,955

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.175, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0000901534-25-000009 · form4-11242025_111128.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,029,955

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.0000 to $87.6708, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0000901534-25-000007 · form4-11212025_031155.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,054,955

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.01 to $86.3499, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0000901534-25-000005 · form4-11202025_091108.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,074,955

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.03 to $86.44, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-023580 · form4-09032025_090916.xml · derivative · entry 8

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/1/2020. Options not vested as of 6/22/2020 have been forfeited.

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-023580 · form4-09032025_090916.xml · derivative · entry 7

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 159,151 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 3/1/2020.

SEC source: 0001415889-25-023580 · form4-09032025_090916.xml · nonDerivative · entry 6

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 8,280.258

F4 · shares: The Reporting Person's spouse surrendered 1,454 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

SEC source: 0001415889-25-023580 · form4-09032025_090916.xml · nonDerivative · entry 5

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 9,734.258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-023580 · form4-09032025_090916.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,079,955

F3 · shares: The Reporting Person surrendered 124,824 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

SEC source: 0001415889-25-023580 · form4-09032025_090916.xml · nonDerivative · entry 3

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,204,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-017043 · form4-06122025_100602.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,045,628

SEC source: 0001415889-25-016204 · form4-06092025_060630.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,046,028

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.10 to $95.32 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-015447 · form4-06032025_090640.xml · nonDerivative · entry 4

Lampropoulos Fred P. · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,056,028

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.01 to $95.23, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-014805 · form4-05292025_050510.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,066,028

F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.32 to $96.99, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 6

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 7,734.258

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 5

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 10,324.259

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,086,028

F4 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $103.765, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 3

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,106,028

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.22, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · derivative · entry 11

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2025-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/2/2019. Options not vested as of 6/22/2020 have been forfeited.

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · derivative · entry 10

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,002 shares

Expires 2025-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 3/2/2019.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 9

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 10,734

F7 · shares: The Reporting Person's spouse surrendered 2,494 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 8

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 13,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 7

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,117,348

F6 · shares: The Reporting Person surrendered 26,043 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 6

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,143,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 5

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,105,389

F5 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,085,005

F4 · shares: The Reporting Person surrendered 13,051 shares of common stock to the Issuer for payroll taxes. No shares were sold in the open market.

SEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 3

LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,098,506

F3 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02/28/2022.

SEC source: 0001415889-24-006975 · form4-03062024_050331.xml · nonDerivative · entry 6

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,067,751

F5 · shares: Reflects shares of Common Stock surrendered by the Reporting Person to satisfy tax withholding obligations in connection with the issuance of the performance stock units. These shares were not sold in an open-market transaction.

SEC source: 0001415889-24-006975 · form4-03062024_050331.xml · nonDerivative · entry 5

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,076,094

F4 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 3/19/2021.

SEC source: 0001415889-24-006975 · form4-03062024_050331.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,057,132

F3 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in four equal annual installments on each of the first four anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting.

SEC source: 0001415889-23-012784 · form4-08292023_100836.xml · derivative · entry 8

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2024-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 4/14/2018. Options not vested as of 6/22/2020 have been forfeited.

F1 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-23-012784 · form4-08292023_100836.xml · derivative · entry 7

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires 2024-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 4/14/2018.

SEC source: 0001415889-23-012784 · form4-08292023_100836.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 9,228

F3 · kind: The Reporting Person's spouse surrendered 3,660 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

F1 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-23-012784 · form4-08292023_100836.xml · nonDerivative · entry 3

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,032,560

F2 · kind: The Reporting Person surrendered 135,356 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

SEC source: 0001415889-23-012784 · form4-08292023_100836.xml · nonDerivative · entry 2

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 12,888

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-23-012784 · form4-08292023_100836.xml · nonDerivative · entry 1

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,167,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-005032 · form4-03162023_100346.xml · nonDerivative · entry 2

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 967,916

F2 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.00 to $68.75 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-23-005032 · form4-03162023_100346.xml · nonDerivative · entry 1

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987,615

F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.99 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-23-003930 · form4-03032023_010313.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 992,893

F4 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.6 to $70.1 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-23-003930 · form4-03032023_010313.xml · nonDerivative · entry 3

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,012,069

F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.44 inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-23-003930 · form4-03032023_010313.xml · derivative · entry 8

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,302

Underlying: Common Stock · 54,302 shares

Expires 2030-02-28

F7 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing 02/28/2024.

SEC source: 0001415889-23-003930 · form4-03032023_010313.xml · nonDerivative · entry 2

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,013,552

F2 · shares: These shares were not sold in an open-market transaction.

SEC source: 0001415889-23-003930 · form4-03032023_010313.xml · nonDerivative · entry 1

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,582

F1 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee and Board of Directors that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.26.2020 and 03.19.2021.

SEC source: 0001415889-22-008572 · form4-08122022_030839.xml · derivative · entry 8

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2023-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Original grant of 7,500 options was to become vested and exercisable in equal annual installments of 20% commencing 1/28/2017. Options not vested as of 6/22/2020 have been forfeited.

F1 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-22-008572 · form4-08122022_030839.xml · derivative · entry 7

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2023-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Became exercisable in equal annual installments of 20% commencing 1/28/2017.

SEC source: 0001415889-22-008572 · form4-08122022_030839.xml · nonDerivative · entry 4

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 6,888

F3 · kind: The Reporting Person's spouse surrendered 2,971 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

F1 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-22-008572 · form4-08122022_030839.xml · nonDerivative · entry 3

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 998,423

F2 · kind: The Reporting Person surrendered 29,341 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market.

SEC source: 0001415889-22-008572 · form4-08122022_030839.xml · nonDerivative · entry 2

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 9,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse.

SEC source: 0001415889-22-008572 · form4-08122022_030839.xml · nonDerivative · entry 1

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,027,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-002081 · form4-03012022_050303.xml · nonDerivative · entry 2

LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 977,764